Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.51) by 40.4 percent. This is a 23.08 percent increase over losses of $(1.17) per share from the same period last year. The company reported quarterly sales of $214.000 million which beat the analyst consensus estimate of $158.777 million by 34.78 percent. This is a 28.53 percent increase over sales of $166.496 million the same period last year.